News
01-27-2011, 10:30 PM
Sanofi-aventis and its subsidiary, BiPar Sciences, today announced that a randomized Phase III trial evaluating iniparib (BSI-201) in patients with metastatic triple-negative breast cancer (mTNBC) did not meet the pre-specified criteria for significance for co-primary endpoints of overall survival and progression-free survival
More... (http://www.news-medical.net/news/20110128/Iniparib-Phase-III-study-in-metastatic-triple-negative-breast-cancer-does-not-meet-primary-goal.aspx)
More... (http://www.news-medical.net/news/20110128/Iniparib-Phase-III-study-in-metastatic-triple-negative-breast-cancer-does-not-meet-primary-goal.aspx)